Vertex Pharmaceutical Company

JSC VERTEX is a St. Petersburg pharmaceutical company with more than 200 product positions in its portfolio: medicines (70% of the portfolio), cosmetics, dietary supplements, and medical products. The company provides a full cycle from development to product packaging in various forms of production: tablets, capsules, ointments, sprays, creams, etc.

About 150 positions in the company's assortment are included in the lines of drugs in cardiology, neurology, psychiatry, allergology, dermatology, gynecology, modern broad-spectrum antibacterial drugs, non-steroidal anti-inflammatory drugs, etc.

Performance indicators

2024: 8.3% revenue cut to ₽22 billion

The pharmaceutical company Vertex recorded a decrease in revenue to ₽22 billion excluding VAT in 2024 against ₽24 billion in 2023, a decrease of 8.3%. The company summed up the preliminary results of its activities and noted the stabilization of financial indicators in the context of a high key rate and the need to adjust some stages of project development. Investments in the company's facilities on the territory of the special economic zone "St. Petersburg" in 2024 exceeded ₽1,8 billion. This became known in August 2025.

According to the press service of Vertex, the final result on revenue will be known by the end of the first quarter of 2025, but it is expected that the indicator will not change. The share of drugs in the volume of sales of the pharmaceutical manufacturer in 2024 traditionally amounted to 90%.

𝓲

Фото: Freepik

About 76% of the drugs sold in physical terms fell on drugs from the list of vital and essential drugs. This sales structure confirms the social significance of the company's activities.

Georgy Pobelyansky, General Director of the Vertex pharmaceutical company, noted that in the current conditions for the company, the stability of financial indicators is the result that management hoped for. Taking into account the size of the key rate and credit obligations, some stages of project development had to be adjusted.

Pobelyansky stressed that the company continued to implement the main projects despite the difficult economic conditions. The Vertex investment program has maintained high rates of implementation of priority development areas.

Vertex allocated more than ₽830 million in 2024 to create a new workshop of hormonal drugs with an area of ​ ​ 1700 square meters. Significant funds were invested in the modernization of the capacities of the second workshop of medicines of the innovation and production complex.^[1]

2023: Annual revenue growth by 24% to RUR 24 billion

At the end of 2023, one of the largest pharmaceutical manufacturers in Russia, Vertex, recorded revenue of 24 billion rubles, which is 24% higher than sales a year ago. The company disclosed such data in mid-February 2024.

According to materials published on the Vertex website, in 2023 the company sold 130 million packages of products, including 120 million packages of drugs. In 2023, about 20 new positions of the pharmaceutical manufacturer's products went on sale, the main part - new dosages, packaging and production forms of drugs available in the portfolio for use in cardiology, otorhinolaryngology, anti-inflammatory and analgesic drugs, etc. By the end of 2023, the number of product positions in the Vertex assortment reached about 380, including about 280 drug positions, taking into account different dosages and packages.

𝓲

Фото: Vertex

In 2023, the company signed a cooperation agreement with St. Petersburg in the implementation of the Pharmrenovation and Import Substitution investment project. Later, Vertex began expanding production by 5.3 thousand square meters. meters and 1.5 thousand square meters. meters - laboratories in the innovation and production complex in the SEZ.

By the end of last year, the company performed 85% of civil construction work at the second facility in the SEZ "St. Petersburg." Its first stage of construction includes a production and warehouse building with an area of ​ ​ more than 22 thousand square meters. m and provides for investments of about 2.4 billion rubles to 2025 inclusive, - said in a statement posted on the Vertex website on February 15, 2024.

The amount of Vertex investments in both facilities since 2010 by the end of 2023 exceeded 10.8 billion rubles.

In 2023, the company increased the number of personnel by 90 people - up to 2060 employees.^[2]

History

2023: Investing 2.1 billion rubles in new production in St. Petersburg

On October 19, 2023, Vertex, one of the largest pharmaceutical manufacturers in Russia, announced the expansion of its production facilities in the special economic zone St. Petersburg at the Novoorlovskaya site. The volume of investments in this project is about 2.1 billion rubles.

Vertex plans to increase the plots by 5.3 thousand m2 over the year, to a total production area of ​ ​ 14 thousand m2. Three production sites will be placed on the new "squares." For example, quality service laboratories and microbiological laboratories will be expanded. According to the plans of the Vertex company, in 2024 the innovation and production complex should be fully mastered.

Vertex announced the expansion of its production capacities in the special economic zone "St. Petersburg"

The construction and equipment of the pharmaceutical complex involves the gradual development of its capabilities. The expansion of production and laboratories is necessary for the urgent needs of the company and the contribution to the drug sovereignty of the country, - said the general director of Vertex Georgy Pobelyansky, whose words are quoted by the company's press service.

The total area of ​ ​ the object is more than 56.5 thousand square meters. m. In addition to production and laboratory facilities, the pharmaceutical complex has storage facilities, auxiliary, administrative and other premises. The company received permits for the commissioning of three stages of the site from 2015 to 2019. At the end of the third quarter of 2023, investments in the facility for the entire project implementation period since 2012 (since the beginning of the design stage) exceeded 9.4 billion rubles.

Earlier in 2023, Vertex signed a cooperation agreement with St. Petersburg in the implementation of the Pharmrenovation and Import Substitution investment project. It involves investments on the part of the pharmaceutical manufacturer in the amount of at least 2 billion rubles and the creation of at least 500 workplaces^[3]

Notes